idera pharmaceuticals inc. Resources | BNET
On CBSNews.com: Can 365 Nights Of Sex Fix A Marriage?

BNET Industries

Idera Pharmaceuticals Inc. (IDRA) is in the Pharma Industry

Revenue
Dec 31 2007
$7.9M
Profit
Dec 31 2007
($13.2M)
Market Cap
Oct 09 2008
$210.4M

Latest News and Analysis

  • Idera Pharmaceuticals Reports Second Quarter 2008 Financial Results

    IMO-3100 Selected as Lead Toll-Like Receptor Antagonist Candidate in Autoimmune Disease Indications CAMBRIDGE, Mass. -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biopharmaceutical company focused on developing therapeutics targeting Toll-Like Receptors TLR, today reported financial results for the second quarter and six months ended June 30, 2008. ...

    Articles 2008-08-04

  • Idera Pharmaceuticals to Present at Upcoming Investor Conferences

    CAMBRIDGE, Mass. -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biopharmaceutical company focused on developing therapeutics targeting Toll-Like Receptors TLR, today announced that it will discuss its TLR-targeted drug discovery and development programs and provide a general corporate overview at the following conferences: * BMO Capital Markets Focus on...

    Articles 2008-07-30

  • Idera Pharmaceuticals Forms Autoimmune Disease Scientific Advisory Board

    CAMBRIDGE, Mass. -- Idera Pharmaceuticals (Nasdaq: IDRA), a biopharmaceutical company focused on developing therapeutics targeting Toll-Like Receptors TLRs, today announced the formation of an Autoimmune Disease Scientific Advisory Board. "We are pleased to have the participation of distinguished clinicians and researchers with extensive experience in...

    Articles 2008-06-16

  • Idera Pharmaceuticals to Present at BIO Business Forum 2008

    CAMBRIDGE, Mass. -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biopharmaceutical company focused on developing therapeutics targeting Toll-Like Receptors TLR, today announced that it will present at the 2008 BIO International Convention taking place June 17-20, 2008 in San Diego, CA. The Company will discuss its TLR-targeted drug...

    Articles 2008-06-13

  • Idera Pharmaceuticals Presents Preclinical Data of Toll-Like Receptor Antagonists in Models of Lung Inflammation and Psoriasis

    CAMBRIDGE, Mass. -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced that presentations from studies evaluating its novel Toll-like Receptor TLR antagonist candidates in preclinical models of lung inflammation and psoriasis were made at the Federation of Clinical Immunology Societies FOCIS 2008 Annual Meeting held in Boston, MA,...

    Articles 2008-06-09

  • page 1 of 1
  • Incorporated: 1989
  • CEO: Dr. Sudhir Agrawal
  • Employees: 38

Idera Pharmaceuticals is a biotechnology company engaged in the discovery and development of deoxyribonucleic acid- and ribonucleic acid-based drug candidates targeted to Toll-Like Receptors (TLRs) to treat infectious diseases, autoimmune diseases, cancer, and asthma and allergies, and for use as vaccine adjuvants. At Dec 31 2007, Co.'s lead drug candidate for infectious disease was IMO-2125, a TLR9 agonist. As of Feb 29 2008, Co. owned 61 U.S. patents and U.S. patent applications and 161 corresponding worldwide patents and patent applications for our TLR-targeted immune modulation technologies.

Key Competitors

advertisement
Idera Pharmaceuticals Inc. Company Info

Board of Directors

Dr. James B. Wyngaarden

Chairman

Mr. Youssef El-Zein

Vice-Chairman

Mr. C. Keith Hartley

Dr. Hans Mueller Ph.D.

Mr. William S. Reardon CPA

Dr. Robert W. Karr M.D.

Dr. Sudhir Agrawal

Dr. Alison Taunton-Rigby Ph.D.

Contact Information

345 Vassar Street

Cambridge, MA

http://www.hybridon.com

617 679-5500

NAICS Code

Biological Product (except Diagnostic) Manufacturing: 325414
advertisement